**FRITS**

**EFFICACY**

**Table : Aneurysm occlusion at 6 months (CORELAB) [ITT - N=152 patients]**

|  | | **FRED / FRED Jr N=98** | **FRED X N=54** | **Total N=152** |
| --- | --- | --- | --- | --- |
|  |  |  |  |  |
| **6M : Aneurysm Occlusion stability** | N | 84 |  | 84 |
|  | Missing data | 14 | 1 | 15 |
|  | Better | 42 (50.0%) | 29 (54.7%) | 71 (51.8%) |
|  | Same | 9 (10.7%) | 6 (11.3%) | 15 (10.9%) |
|  | Cannot be assessed from the imaging | 33 (39.3%) | 18 (34.0%) | 51 (37.2%) |
|  | Between group test |  |  | 0.820 (Chi-2) |

**FRITS**

**EFFICACY**

**Table : Aneurysm occlusion at 12 months (CORELAB) [ITT - N=152 patients]**

|  | | **FRED / FRED Jr N=98** | **FRED X N=54** | **Total N=152** |
| --- | --- | --- | --- | --- |
|  |  |  |  |  |
| **1Y : Aneurysm Occlusion stability** | N | 88 |  | 88 |
|  | Missing data | 10 | 5 | 15 |
|  | Better | 42 (47.7%) | 19 (38.8%) | 61 (44.5%) |
|  | Same | 31 (35.2%) | 20 (40.8%) | 51 (37.2%) |
|  | Cannot be assessed from the imaging | 15 (17.0%) | 10 (20.4%) | 25 (18.2%) |
|  | Between group test |  |  | 0.599 (Chi-2) |

**FRITS**

**EFFICACY**

**Table : Evolution of aneurysm occlusion between 6 months and 12 months (CORELAB) [ITT - N=152 patients]**

|  |
| --- |
| ***La procédure FREQ*** |

**Subgroup device=FRED / FRED Jr**

| **CL6MAOS** | **CL1YAOS** | **Fréquence** | **Fréquence cumulée** |
| --- | --- | --- | --- |
| **.** | **.** | 4 | 4 |
| **.** | **Better** | 2 | 6 |
| **ND** | **Better** | 5 | 11 |
| **ND** | **Same** | 3 | 14 |
| **Better** | **.** | 2 | 16 |
| **Better** | **ND** | 2 | 18 |
| **Better** | **Better** | 11 | 29 |
| **Better** | **Same** | 16 | 45 |
| **Better** | **Cannot be assessed from the imaging** | 11 | 56 |
| **Same** | **.** | 1 | 57 |
| **Same** | **Better** | 2 | 59 |
| **Same** | **Same** | 5 | 64 |
| **Same** | **Cannot be assessed from the imaging** | 1 | 65 |
| **Cannot be assessed from the imaging** | **.** | 1 | 66 |
| **Cannot be assessed from the imaging** | **Better** | 22 | 88 |
| **Cannot be assessed from the imaging** | **Same** | 7 | 95 |
| **Cannot be assessed from the imaging** | **Cannot be assessed from the imaging** | 3 | 98 |

**FRITS**

**EFFICACY**

**Table : Evolution of aneurysm occlusion between 6 months and 12 months (CORELAB) [ITT - N=152 patients]**

|  |
| --- |
| ***La procédure FREQ*** |

**Subgroup device=FRED X**

| **CL6MAOS** | **CL1YAOS** | **Fréquence** | **Fréquence cumulée** |
| --- | --- | --- | --- |
| **.** | **.** | 1 | 1 |
| **Better** | **.** | 2 | 3 |
| **Better** | **Better** | 7 | 10 |
| **Better** | **Same** | 14 | 24 |
| **Better** | **Cannot be assessed from the imaging** | 6 | 30 |
| **Same** | **.** | 1 | 31 |
| **Same** | **Better** | 1 | 32 |
| **Same** | **Same** | 2 | 34 |
| **Same** | **Cannot be assessed from the imaging** | 2 | 36 |
| **Cannot be assessed from the imaging** | **ND** | 1 | 37 |
| **Cannot be assessed from the imaging** | **Better** | 11 | 48 |
| **Cannot be assessed from the imaging** | **Same** | 4 | 52 |
| **Cannot be assessed from the imaging** | **Cannot be assessed from the imaging** | 2 | 54 |

**FRITS**

**EFFICACY**

**Table : Aneurysm occlusion at 6 months (CORELAB) [PP - N=136 patients]**

|  | | **FRED / FRED Jr N=86** | **FRED X N=50** | **Total N=136** |
| --- | --- | --- | --- | --- |
|  |  |  |  |  |
| **6M : Aneurysm Occlusion stability** | N | 74 |  | 74 |
|  | Missing data | 12 | 1 | 13 |
|  | Better | 36 (48.6%) | 27 (55.1%) | 63 (51.2%) |
|  | Same | 8 (10.8%) | 6 (12.2%) | 14 (11.4%) |
|  | Cannot be assessed from the imaging | 30 (40.5%) | 16 (32.7%) | 46 (37.4%) |
|  | Between group test |  |  | 0.676 (Chi-2) |

**FRITS**

**EFFICACY**

**Table : Aneurysm occlusion at 12 months (CORELAB) [PP - N=136 patients]**

|  | | **FRED / FRED Jr N=86** | **FRED X N=50** | **Total N=136** |
| --- | --- | --- | --- | --- |
|  |  |  |  |  |
| **1Y : Aneurysm Occlusion stability** | N | 80 |  | 80 |
|  | Missing data | 6 | 5 | 11 |
|  | Better | 38 (47.5%) | 15 (33.3%) | 53 (42.4%) |
|  | Same | 27 (33.8%) | 20 (44.4%) | 47 (37.6%) |
|  | Cannot be assessed from the imaging | 15 (18.8%) | 10 (22.2%) | 25 (20.0%) |
|  | Between group test |  |  | 0.299 (Chi-2) |

**FRITS**

**EFFICACY**

**Table : Evolution of aneurysm occlusion between 6 months and 12 months (CORELAB) [PP - N=136 patients]**

|  |
| --- |
| ***La procédure FREQ*** |

**Subgroup device=FRED / FRED Jr**

| **CL6MAOS** | **CL1YAOS** | **Fréquence** | **Fréquence cumulée** |
| --- | --- | --- | --- |
| **.** | **.** | 4 | 4 |
| **.** | **Better** | 2 | 6 |
| **ND** | **Better** | 5 | 11 |
| **ND** | **Same** | 1 | 12 |
| **Better** | **ND** | 1 | 13 |
| **Better** | **Better** | 8 | 21 |
| **Better** | **Same** | 16 | 37 |
| **Better** | **Cannot be assessed from the imaging** | 11 | 48 |
| **Same** | **Better** | 2 | 50 |
| **Same** | **Same** | 5 | 55 |
| **Same** | **Cannot be assessed from the imaging** | 1 | 56 |
| **Cannot be assessed from the imaging** | **.** | 1 | 57 |
| **Cannot be assessed from the imaging** | **Better** | 21 | 78 |
| **Cannot be assessed from the imaging** | **Same** | 5 | 83 |
| **Cannot be assessed from the imaging** | **Cannot be assessed from the imaging** | 3 | 86 |

**FRITS**

**EFFICACY**

**Table : Evolution of aneurysm occlusion between 6 months and 12 months (CORELAB) [PP - N=136 patients]**

|  |
| --- |
| ***La procédure FREQ*** |

**Subgroup device=FRED X**

| **CL6MAOS** | **CL1YAOS** | **Fréquence** | **Fréquence cumulée** |
| --- | --- | --- | --- |
| **.** | **.** | 1 | 1 |
| **Better** | **.** | 2 | 3 |
| **Better** | **Better** | 5 | 8 |
| **Better** | **Same** | 14 | 22 |
| **Better** | **Cannot be assessed from the imaging** | 6 | 28 |
| **Same** | **.** | 1 | 29 |
| **Same** | **Better** | 1 | 30 |
| **Same** | **Same** | 2 | 32 |
| **Same** | **Cannot be assessed from the imaging** | 2 | 34 |
| **Cannot be assessed from the imaging** | **ND** | 1 | 35 |
| **Cannot be assessed from the imaging** | **Better** | 9 | 44 |
| **Cannot be assessed from the imaging** | **Same** | 4 | 48 |
| **Cannot be assessed from the imaging** | **Cannot be assessed from the imaging** | 2 | 50 |